Ocrelizumab in treatment of primary-progressive multiple sclerosis: systematic review

Aim. To analyze the efficacy, safety and pharmacoeconomic indicators of ocrelizumab in adult patients with primary progressive multiple sclerosis (PPMS). Methods. An information search was conducted in the databases Embase, PubMed, Cochrane and eLibrary.ru. The levels of evidence were determined in...

Descrición completa

Gardado en:

Detalles Bibliográficos
Principais autores:	D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, E. M. Olyushina, K. I. Polyakova, A. G. Fisun, M. G. Grinin, K. A. Kokushkin
Formato:	Artigo
Idioma:	Russo
Publicado:	Izdatelstvo OKI 2018-07-01
Series:	Качественная клиническая практика
Assuntos:	окрелизумаб эффективность безопасность систематический обзор первично-прогрессирующий рассеянный склероз анти-в-клеточная терапия моноклональные антитела
Acceso en liña:	https://www.clinvest.ru/jour/article/view/405
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Ocrelizumab in treatment of primary-progressive multiple sclerosis: systematic review

Títulos similares